EpiCast Report: Acute Coronary Syndrome – Epidemiology Forecast to 2025

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

GlobalData epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 million cases in 2015 to 30.62 million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%. In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM. In the 7MM, GlobalData epidemiologists project ACS hospitalizations to increase from 1.63 million cases in 2015 to 1.71 million cases in 2025 at an AGR of 0.51%. The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%). In the year 2015, about 29% of the ACS cases in the 7MM were STEMI, 44% were NSTEMI, and 25% were UA.

Scope

The Acute coronary syndrome (ACS) EpiCast Report and EpiCast Model provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015–2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).

The ACS epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Epidemiology

2.1Disease Background

2.2Risk Factors and Comorbidities

2.3Global Trends

2.3.1ACS Diagnosed Prevalence

2.3.2STEMI and NSTEMI Trends

2.3.3ACS Hospitalizations

2.4Forecast Methodology

2.4.1Sources Used

2.4.2Forecast Assumptions and Methods

2.4.3Sources Not Used

2.5Epidemiological Forecast for ACS (2015–2025)

2.5.1Diagnosed Prevalent Cases of ACS

2.5.2Age–Specific Diagnosed Prevalent Cases of ACS

2.5.3Sex-Specific Diagnosed Prevalent Cases of ACS

2.5.4Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA

2.5.5Age-Standardized Diagnosed Prevalence of ACS

2.5.6ACS Hospitalizations

2.5.7Sex-Specific ACS Hospitalizations

2.5.8ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA

2.6Discussion

2.6.1Epidemiological Forecast Insight

2.6.2Limitations of the Analysis

2.6.3Strengths of the Analysis

3Appendix

3.1Bibliography

3.2About the Authors

3.2.1Epidemiologists

3.2.2Reviewers

3.2.3Global Director of Therapy Analysis and Epidemiology

3.2.4Global Head of Healthcare

3.3About GlobalData

3.4About EpiCast

3.5Disclaimer

List of Tables

Table 1: Risk Factors and Comorbidities for ACS

Table 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants

Table 3: 7MM, Sources of Diagnosed Prevalence Data for MI

Table 4: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI

Table 5: 7MM, Data Sources of ACS Hospitalizations

Table 6: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations

Table 7: 7MM, Diagnosed Prevalent Cases of ACS, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Table 8: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015

Table 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages =25 Years, N (Row %), 2015

Table 10: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages =25 Years, N (Row %), 2015

Table 11: 7MM ACS Hospitalizations, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Table 12: 7MM, Sex-Specific ACS Hospitalizations, Ages =25 Years, N (Row %), 2015

Table 13: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages =25 Years, Both Sexes, N, 2015

List of Figures

Figure 1: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990–2008

Figure 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%)

Figure 3: Case Segmentation Map

Figure 4: 7MM, Diagnosed Prevalent Cases of ACS, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Figure 5; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015

Figure 6: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages =25 Years, N, 2015

Figure 7: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages =25 Years, N, 2015

Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages =25 Years, 2015

Figure 9: 7MM ACS Hospitalizations, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Figure 10: 7MM, Sex-Specific ACS, Ages =25 Years, N, 2015

Figure 11: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages =25 Years, Both Sexes, N, 2015

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports